International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 038-043
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Evaluation of Autologous Hematopoietic Stem Cell Transplantation Results of the Patients with Hodgkin Lymphoma: A Single Center Experience
Tugba TURGUT1, Eren GUNDUZ2, O. Meltem AKAY2, Hava U. TEKE2, Ozge BOLLUK3, Zafer GULBAS4
1Eskisehir Osmangazi University Faculty of Medicine Department of Internal Medicine Eskisehir, TURKEY
2Eskisehir Osmangazi University Faculty of Medicine Department of Hematology Eskisehir, TURKEY
3Eskisehir Osmangazi University School of Medicine Department of Biostatistics Eskisehir, TURKEY
4Anadolu Health Center Bone Marrow Transplantation Center, Eskisehir, TURKEY
Keywords: Hodgkin lymphoma, Autologous transplantation, Hematopoietic stem cells, Prognosis, Survival
In this study data of 45 patients with Hodgkin lymphoma who underwent autologous hematopoietic stem cell transplantation between July 2000 and January 2012 were evaluated retrospectively. Clinical, laboratory and demographic characteristics affecting disease free survival (DFS) and overall survival (OS) were evaluated. Relapse and mortality rates in second and fifth years were also calculated. According to our results, patients in remission status before transplantation had a longer OS (p= 0.031) and relapse after transplantation shortened OS (p= 0.016). High beta 2 microglobulin level was associated with a shorter disease free survival (p= 0.042). Four patients (8.8%) died and 14 patients (31.1%) relapsed in the second year; 7 patients (%15.5) died and 17 patients (37.7%) relapsed in the fifth year. Median survival was 39 (6-72) months. In conclusion, autologous hematopoietic stem cell transplantation can be a salvage treatment for selected Hodgkin lymphoms patients who relapsed but it is important to evaluate prognostic factors and long term outcomes in terms of relapse and mortality after transplantation. Sharing experience from different transplantation centers can help selecting the most suitable patient for autologous transplantation.
Tugba TURGUT1, Eren GUNDUZ2, O. Meltem AKAY2, Hava U. TEKE2, Ozge BOLLUK3, Zafer GULBAS4
1Eskisehir Osmangazi University Faculty of Medicine Department of Internal Medicine Eskisehir, TURKEY
2Eskisehir Osmangazi University Faculty of Medicine Department of Hematology Eskisehir, TURKEY
3Eskisehir Osmangazi University School of Medicine Department of Biostatistics Eskisehir, TURKEY
4Anadolu Health Center Bone Marrow Transplantation Center, Eskisehir, TURKEY
Keywords: Hodgkin lymphoma, Autologous transplantation, Hematopoietic stem cells, Prognosis, Survival
In this study data of 45 patients with Hodgkin lymphoma who underwent autologous hematopoietic stem cell transplantation between July 2000 and January 2012 were evaluated retrospectively. Clinical, laboratory and demographic characteristics affecting disease free survival (DFS) and overall survival (OS) were evaluated. Relapse and mortality rates in second and fifth years were also calculated. According to our results, patients in remission status before transplantation had a longer OS (p= 0.031) and relapse after transplantation shortened OS (p= 0.016). High beta 2 microglobulin level was associated with a shorter disease free survival (p= 0.042). Four patients (8.8%) died and 14 patients (31.1%) relapsed in the second year; 7 patients (%15.5) died and 17 patients (37.7%) relapsed in the fifth year. Median survival was 39 (6-72) months. In conclusion, autologous hematopoietic stem cell transplantation can be a salvage treatment for selected Hodgkin lymphoms patients who relapsed but it is important to evaluate prognostic factors and long term outcomes in terms of relapse and mortality after transplantation. Sharing experience from different transplantation centers can help selecting the most suitable patient for autologous transplantation.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |